Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.

Voss MH, Bhatt RS, Vogelzang NJ, Fishman M, Alter RS, Rini BI, Beck JT, Joshi M, Hauke R, Atkins MB, Burgess E, Logan TF, Shaffer D, Parikh R, Moazzam N, Zhang X, Glasser C, Sherman ML, Plimack ER.

Cancer. 2019 Jul 15;125(14):2400-2408. doi: 10.1002/cncr.32061. Epub 2019 Apr 5.

PMID:
30951193
2.

Navigating a 'Perfect Storm' on the Path to Prevention of Type 2 Diabetes Mellitus After Gestational Diabetes: Lessons from Patient and Provider Narratives.

McCloskey L, Sherman ML, St John M, Siegel H, Whyte J, Iverson R, Lee-Parritz A, Bernstein J.

Matern Child Health J. 2019 May;23(5):603-612. doi: 10.1007/s10995-018-2649-0.

PMID:
30949932
3.

Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia.

Piga A, Perrotta S, Gamberini MR, Voskaridou E, Melpignano A, Filosa A, Caruso V, Pietrangelo A, Longo F, Tartaglione I, Borgna-Pignatti C, Zhang X, Laadem A, Sherman ML, Attie KM.

Blood. 2019 Mar 21;133(12):1279-1289. doi: 10.1182/blood-2018-10-879247. Epub 2019 Jan 7.

4.

A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma.

Abou-Alfa GK, Miksad RA, Tejani MA, Williamson S, Gutierrez ME, Olowokure OO, Sharma MR, El Dika I, Sherman ML, Pandya SS.

Oncologist. 2019 Feb;24(2):161-e70. doi: 10.1634/theoncologist.2018-0654. Epub 2018 Oct 23.

5.

Locally acting ACE-083 increases muscle volume in healthy volunteers.

Glasser CE, Gartner MR, Wilson D, Miller B, Sherman ML, Attie KM.

Muscle Nerve. 2018 Jun;57(6):921-926. doi: 10.1002/mus.26113. Epub 2018 Mar 15.

6.

Exploring How Live Theaters Promote Participation for Children with Special Needs.

Fletcher TS, Parrish JL, Sherman ML.

Phys Occup Ther Pediatr. 2018 May;38(2):157-167. doi: 10.1080/01942638.2017.1368056. Epub 2017 Sep 13.

PMID:
28901814
7.

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.

Platzbecker U, Germing U, Götze KS, Kiewe P, Mayer K, Chromik J, Radsak M, Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A.

Lancet Oncol. 2017 Oct;18(10):1338-1347. doi: 10.1016/S1470-2045(17)30615-0. Epub 2017 Sep 1. Erratum in: Lancet Oncol. 2017 Oct;18(10):e562.

PMID:
28870615
8.

The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.

Voss MH, Bhatt RS, Plimack ER, Rini BI, Alter RS, Beck JT, Wilson D, Zhang X, Mutyaba M, Glasser C, Attie KM, Sherman ML, Pandya SS, Atkins MB.

Clin Cancer Res. 2017 Jul 15;23(14):3557-3565. doi: 10.1158/1078-0432.CCR-16-2395. Epub 2016 Dec 28.

9.

Dandy-Walker Malformation: A Case Study of an Infant With an Increasing Head Circumference and Delayed Developmental Milestones.

Sherman ML, Close S, Weselman B.

J Pediatr Health Care. 2017 May - Jun;31(3):398-403. doi: 10.1016/j.pedhc.2016.11.008. Epub 2016 Dec 22. No abstract available.

PMID:
28017487
10.

A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, Popa EC, Argiris A, Grossmann KF, Sukari A, Wilson D, Zhang X, Sun J, Glasser C, Attie KM, Sherman ML, Pandya SS, Weiss J.

Cancer. 2016 Dec 1;122(23):3641-3649. doi: 10.1002/cncr.30317. Epub 2016 Sep 20.

11.

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.

Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, Wilson DM, Sherman ML, Escolar D, Attie KM.

Muscle Nerve. 2017 Apr;55(4):458-464. doi: 10.1002/mus.25268. Epub 2016 Dec 23.

PMID:
27462804
12.

Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies.

Raftopoulos H, Laadem A, Hesketh PJ, Goldschmidt J, Gabrail N, Osborne C, Ali M, Sherman ML, Wang D, Glaspy JA, Puccio-Pick M, Zou J, Crawford J.

Support Care Cancer. 2016 Apr;24(4):1517-25. doi: 10.1007/s00520-015-2929-9. Epub 2015 Sep 14.

13.

A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers.

Attie KM, Allison MJ, McClure T, Boyd IE, Wilson DM, Pearsall AE, Sherman ML.

Am J Hematol. 2014 Jul;89(7):766-70. doi: 10.1002/ajh.23732. Epub 2014 Apr 26.

14.

Sotatercept in patients with osteolytic lesions of multiple myeloma.

Abdulkadyrov KM, Salogub GN, Khuazheva NK, Sherman ML, Laadem A, Barger R, Knight R, Srinivasan S, Terpos E.

Br J Haematol. 2014 Jun;165(6):814-23. doi: 10.1111/bjh.12835. Epub 2014 Mar 21.

15.

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer.

Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, Agarwal N, Condon CH, Wilson D, Pearsall AE, Yang Y, McClure T, Attie KM, Sherman ML, Sharma S.

Clin Cancer Res. 2014 Jan 15;20(2):480-9. doi: 10.1158/1078-0432.CCR-13-1840. Epub 2013 Oct 30.

16.

Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women.

Sherman ML, Borgstein NG, Mook L, Wilson D, Yang Y, Chen N, Kumar R, Kim K, Laadem A.

J Clin Pharmacol. 2013 Nov;53(11):1121-30. doi: 10.1002/jcph.160. Epub 2013 Sep 9.

17.

A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers.

Attie KM, Borgstein NG, Yang Y, Condon CH, Wilson DM, Pearsall AE, Kumar R, Willins DA, Seehra JS, Sherman ML.

Muscle Nerve. 2013 Mar;47(3):416-23. doi: 10.1002/mus.23539. Epub 2012 Nov 21.

PMID:
23169607
18.

Activin receptor antagonists for cancer-related anemia and bone disease.

Fields SZ, Parshad S, Anne M, Raftopoulos H, Alexander MJ, Sherman ML, Laadem A, Sung V, Terpos E.

Expert Opin Investig Drugs. 2013 Jan;22(1):87-101. doi: 10.1517/13543784.2013.738666. Epub 2012 Nov 6. Review.

PMID:
23127248
19.

Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women.

Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R, Underwood KW, Seehra J, Yang Y, Condon CH, Sherman ML.

J Bone Miner Res. 2009 Apr;24(4):744-52. doi: 10.1359/jbmr.081208.

20.

Clinical intake of child and adolescent consumers in a rural community mental health center: does wait-time predict attendance?

Sherman ML, Barnum DD, Buhman-Wiggs A, Nyberg E.

Community Ment Health J. 2009 Feb;45(1):78-84. doi: 10.1007/s10597-008-9153-8. Epub 2008 Sep 20.

PMID:
18807182
21.

Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors.

Berkenblit A, Eder JP Jr, Ryan DP, Seiden MV, Tatsuta N, Sherman ML, Dahl TA, Dezube BJ, Supko JG.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):584-90.

22.

A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides.

Duvic M, Sherman ML, Wood GS, Kuzel TM, Olsen E, Foss F, Laliberté RJ, Ryan JL, Zonno K, Rook AH.

J Am Acad Dermatol. 2006 Nov;55(5):807-13. Epub 2006 Sep 8.

PMID:
17052486
23.

Measurement of coping and stress responses in women with breast cancer.

Compas BE, Beckjord E, Agocha B, Sherman ML, Langrock A, Grossman CI, Dausch B, Glinder J, Kaiser C, Anderson-Hanley C, Luecken L.

Psychooncology. 2006 Dec;15(12):1038-54.

PMID:
17009343
24.

A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease.

Burakoff R, Barish CF, Riff D, Pruitt R, Chey WY, Farraye FA, Shafran I, Katz S, Krone CL, Vander Vliet M, Stevens C, Sherman ML, Jacobson E, Bleday R.

Inflamm Bowel Dis. 2006 Jul;12(7):558-65.

PMID:
16804392
25.

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.

Larson RA, Sievers EL, Stadtmauer EA, Löwenberg B, Estey EH, Dombret H, Theobald M, Voliotis D, Bennett JM, Richie M, Leopold LH, Berger MS, Sherman ML, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR.

Cancer. 2005 Oct 1;104(7):1442-52.

26.

Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.

Arceci RJ, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R, Vik TA, Flowers D, Aplenc R, Berger MS, Sherman ML, Smith FO, Bernstein I, Sievers EL.

Blood. 2005 Aug 15;106(4):1183-8. Epub 2005 May 10.

PMID:
15886328
27.

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML.

J Clin Oncol. 2004 Mar 1;22(5):909-18.

PMID:
14990647
28.

Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature.

Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE.

J Int Neuropsychol Soc. 2003 Nov;9(7):967-82.

PMID:
14738279
29.

Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma.

Cebon J, Jäger E, Shackleton MJ, Gibbs P, Davis ID, Hopkins W, Gibbs S, Chen Q, Karbach J, Jackson H, MacGregor DP, Sturrock S, Vaughan H, Maraskovsky E, Neumann A, Hoffman E, Sherman ML, Knuth A.

Cancer Immun. 2003 Jul 16;3:7.

30.

Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder.

Weiss GR, O'Donnell MA, Loughlin K, Zonno K, Laliberte RJ, Sherman ML.

J Immunother. 2003 Jul-Aug;26(4):343-8.

PMID:
12843796
31.

A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma.

Chan SY, Gordon AN, Coleman RE, Hall JB, Berger MS, Sherman ML, Eten CB, Finkler NJ.

Cancer Immunol Immunother. 2003 Apr;52(4):243-8. Epub 2003 Feb 26.

PMID:
12669249
32.

Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse.

Berger MS, Leopold LH, Dowell JA, Korth-Bradley JM, Sherman ML.

Invest New Drugs. 2002 Nov;20(4):395-406. Review.

PMID:
12448657
33.

Chemical orientation of brown bullheads, Ameiurus nebulosus, under different flow conditions.

Sherman ML, Moore PA.

J Chem Ecol. 2001 Nov;27(11):2301-18.

PMID:
11817083
34.

Patient "uncontrolled" analgesia.

Bitetti JM, Sherman ML.

Anesthesiology. 2001 Nov;95(5):1306. No abstract available.

PMID:
11685016
35.

The role for interleukin-12 therapy of cutaneous T cell lymphoma.

Rook AH, Zaki MH, Wysocka M, Wood GS, Duvic M, Showe LC, Foss F, Shapiro M, Kuzel TM, Olsen EA, Vonderheid EC, Laliberte R, Sherman ML.

Ann N Y Acad Sci. 2001 Sep;941:177-84.

PMID:
11594571
36.

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.

Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR; Mylotarg Study Group.

J Clin Oncol. 2001 Jul 1;19(13):3244-54.

PMID:
11432892
37.

Bilateral eventration of the diaphragm with perforated gastric volvulus in an adolescent.

Oh A, Gulati G, Sherman ML, Golub R, Kutin N.

J Pediatr Surg. 2000 Dec;35(12):1824-6.

PMID:
11101746
38.

Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses.

Rook AH, Wood GS, Yoo EK, Elenitsas R, Kao DM, Sherman ML, Witmer WK, Rockwell KA, Shane RB, Lessin SR, Vonderheid EC.

Blood. 1999 Aug 1;94(3):902-8.

PMID:
10419880
39.

Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.

Robertson MJ, Cameron C, Atkins MB, Gordon MS, Lotze MT, Sherman ML, Ritz J.

Clin Cancer Res. 1999 Jan;5(1):9-16.

40.

Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL.

Blood. 1997 Oct 1;90(7):2541-8.

PMID:
9326219
41.

Intraventricular hemorrhage and fetal heart rate in very low birth weight infants.

Casey BM, Nathan L, Leveno KJ, Perlman JM, Sherman ML.

J Perinatol. 1997 May-Jun;17(3):208-12.

PMID:
9210076
42.

Quality control for DNA contamination in laboratories using PCR-based class II HLA typing methods.

McCormack JM, Sherman ML, Maurer DH.

Hum Immunol. 1997 Apr 15;54(1):82-8.

PMID:
9154462
43.

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML.

Clin Cancer Res. 1997 Mar;3(3):409-17.

44.

Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma.

Jakubowski AA, Bajorin DF, Templeton MA, Chapman PB, Cody BV, Thaler H, Tao Y, Filippa DA, Williams L, Sherman ML, Garnick MB, Houghton AN.

Clin Cancer Res. 1996 Feb;2(2):295-302.

45.

Randomized investigation of antimicrobials for the prevention of preterm birth.

Cox SM, Bohman VR, Sherman ML, Leveno KJ.

Am J Obstet Gynecol. 1996 Jan;174(1 Pt 1):206-10.

PMID:
8572007
46.
47.

Maternal youth and pregnancy outcomes: middle school versus high school age groups compared with women beyond the teen years.

Satin AJ, Leveno KJ, Sherman ML, Reedy NJ, Lowe TW, McIntire DD.

Am J Obstet Gynecol. 1994 Jul;171(1):184-7.

PMID:
8030697
48.

Meconium: a 1990s perspective on an old obstetric hazard.

Nathan L, Leveno KJ, Carmody TJ 3rd, Kelly MA, Sherman ML.

Obstet Gynecol. 1994 Mar;83(3):329-32.

PMID:
8127520
49.

High-dose oxytocin: 20- versus 40-minute dosage interval.

Satin AJ, Leveno KJ, Sherman ML, McIntire D.

Obstet Gynecol. 1994 Feb;83(2):234-8.

PMID:
8290186
50.

Effect of a novel antifolate, N alpha-(4-amino-4-deoxypteroyl)-N delta-hemiphthaloyl-L-ornithine (PT523), on growth of H35 rat hepatoma and HEPG2 human hepatoma cells.

Rhee MS, Galivan J, Tyobeka EM, Sherman ML, Rosowsky A.

Adv Exp Med Biol. 1993;338:461-4. No abstract available.

PMID:
8304158

Supplemental Content

Loading ...
Support Center